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Abstract
Streptococcus pneumoniae serotype 3 remains a significant cause of morbidity and mortal-
ity worldwide, despite inclusion in the 13-valent pneumococcal conjugate vaccine (PCV13).
Serotype 3 increased in carriage since the implementation of PCV13 in the USA, while inva-
sive disease rates remain unchanged. We investigated the persistence of serotype 3 in car-
riage and disease, through genomic analyses of a global sample of 301 serotype 3 isolates
of the Netherlands3–31 (PMEN31) clone CC180, combined with associated patient data
and PCV utilization among countries of isolate collection. We assessed phenotypic variation
between dominant clades in capsule charge (zeta potential), capsular polysaccharide shed-
ding, and susceptibility to opsonophagocytic killing, which have previously been associated
with carriage duration, invasiveness, and vaccine escape. We identified a recent shift in the
CC180 population attributed to a lineage termed Clade II, which was estimated by Bayesian
coalescent analysis to have first appeared in 1968 [95% HPD: 1939–1989] and increased in
prevalence and effective population size thereafter. Clade II isolates are divergent from the
pre-PCV13 serotype 3 population in non-capsular antigenic composition, competence, and
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antibiotic susceptibility, the last of which resulting from the acquisition of a Tn916-like conju-
gative transposon. Differences in recombination rates among clades correlated with varia-
tions in the ATP-binding subunit of Clp protease, as well as amino acid substitutions in the
comCDE operon. Opsonophagocytic killing assays elucidated the low observed efficacy of
PCV13 against serotype 3. Variation in PCV13 use among sampled countries was not inde-
pendently correlated with the CC180 population shift; therefore, genotypic and phenotypic
differences in protein antigens and, in particular, antibiotic resistance may have contributed
to the increase of Clade II. Our analysis emphasizes the need for routine, representative
sampling of isolates from disperse geographic regions, including historically under-sampled
areas. We also highlight the value of genomics in resolving antigenic and epidemiological
variations within a serotype, which may have implications for future vaccine development.
Author summary
Streptococcus pneumoniae is a leading cause of bacterial pneumoniae, meningitis, and oti-
tis media. Despite its inclusion in the most recent pneumococcal conjugate vaccine,
PCV13, serotype 3 remains epidemiologically important globally. We investigated the per-
sistence of serotype 3 using whole-genome sequencing data from 301 isolates collected
among 24 countries from 1993–2014. Through phylogenetic analysis, we identified three
distinct lineages within a single clonal complex, CC180, and found one that has recently
emerged and grown in prevalence. We then compared genomic difference among lineages
as well as variations in pneumococcal vaccine use among sampled countries. We found
that the recently emerged lineage, termed Clade II, has a higher prevalence of antibiotic
resistance compared to other lineages, diverse surface protein antigens, and a higher rate
of recombination, a process by which bacteria can uptake and incorporate genetic mate-
rial from its surroundings. Differences in vaccine use among sampled countries did not
appear to be associated with the emergence of Clade II. We highlight the need for routine,
representative sampling of bacterial isolates from diverse geographic areas and show
the utility of genomic data in resolving epidemiological differences within a pathogen
population.
Introduction
Pneumococcal disease caused by Streptococcus pneumoniae remains a significant cause of mor-
bidity and mortality even in the era of effective conjugate vaccines, which protect against up to
13 of the nearly 100 known serotypes [1]. Serotype is based on biochemical and antigenic
properties of the polysaccharide capsule, a key virulence factor encoded by the capsular (cps)
locus and the target of the pneumococcal conjugate vaccines (PCV). Among those serotypes
covered by the 13-valent pneumococcal conjugate vaccine (PCV13), serotype 3 is considered
highly invasive and is associated with a high risk of mortality in both observational studies and
animal models [2–5]. However, the serotype-specific effectiveness of PCV13 against serotype 3
remains uncertain. There has been little reduction in serotype 3 disease compared to disease
due to other vaccine serotypes following implementation of PCV13 in the USA (Fig 1) [6]. In
addition, data from a randomized controlled trials on nasopharyngeal carriage [7], post-licen-
sure studies of PCV13 on invasive pneumococcal disease (IPD) [8], and national surveillance
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data on IPD from England and Wales [9,10], among other studies have shown little vaccine
effect on serotype 3.
Pneumococci can be divided into lineages, often referred to as sequence clusters, based on
statistical analysis of nucleotide diversity in the core genome [11–13]. In general, lineages are
often comprised of strains possessing the same multi-locus sequence typing (MLST) and sero-
type. However, whereas MLST profiles are unlikely to appear in multiple lineages, the same
serotype may be distributed across the population due to the transfer of the genes encoding
the capsule between lineages by homologous recombination [14]. MLSTs can be further
grouped into clonal complexes (CCs) [15]. For serotype 3, MLST data have shown that the
majority of isolates globally are a single CC of closely related genotypes (CC180) also known as
the Netherlands3–31 (PMEN31) clone [16–19], with the exception of Africa where non-CC180
MLST types are prevalent [20].
However, more recent genomic studies have shown that CC180 contains multiple distinct
lineages [18,21], which MLST is not sufficiently discriminating to detect. While one of these
lineages (termed ‘Clade I’) accounts for almost all previously studied genomes, the overwhelm-
ing majority (92%) of these isolates came from European collections, and might not be repre-
sentative of the global pneumococcal population.
Fig 1. Changes in the incidence of invasive pneumococcal disease (IPD) from 2004 through 2013 among all ages and vaccine
status in the United States based on CDC Active Bacterial Core (ABC) surveillance data [6]. Rates of IPD expressed as cases per
100,000 population are on the y-axis, and calendar year of surveillance are on the x-axis. The green line represents the IPD rate for the
five most common non-PCV13 serotypes; purple line, the rate for serotype 3 only; orange line, the rate of (PCV13 –serotype 3)
serotypes containing (1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Further information can be obtained from the CDC’s ABC
surveillance (www.cdc.gov/abcs/).
https://doi.org/10.1371/journal.ppat.1007438.g001
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Following roll-out of PCV13, an unexpected increase in the carriage prevalence of serotype
3 was noted among Massachusetts children less than seven years of age [22]. Initial genomic
analysis of these carriage isolates showed a change in the serotype 3 population [23]. Prior to
vaccination the majority of isolates fell into the previously described ‘Clade I’, while following
PCV13 introduction, the observed increase in carriage prevalence was largely due to isolates
which, while still CC180, were drawn from a more diverse population that has been poorly
represented in prior samples. Phenotypic variations within CC180 and how they may relate to
vaccine efficacy have not been investigated and remain poorly understood.
To investigate the population structure and evolutionary history of serotype 3 CC180 pneu-
mococci, we conducted a genomic analysis of 301 serotype 3 CC180 isolates from carriage and
disease collected from 24 countries over 20 years. Further, we assessed multiple phenotypic
features linked to the epidemiology of serotype 3, and which might contribute to vaccine
escape including reaction to PCV13 antisera, and how they vary in the CC180 population
[24–26].
Methods
Study population and epidemiological data
The sample consisted of 301 CC180 (PMEN31) genomes collected from carriage (n = 68),
invasive disease (n = 231), and unknown clinical manifestations (n = 2) between 1993–2014.
Whole-genome sequencing (WGS) data for this sample were obtained from a previous analysis
of serotype 3 described elsewhere (n = 82) [18], on-going studies of carriage in Massachusetts,
USA (n = 27) [12], carriage studies in the Southwest USA (n = 14) [27], the Bacterial Isolate
Genome Sequence database (BIGSDB) (n = 10), and the Global Pneumococcal Sequencing
(GPS) project (http://www.pneumogen.net/gps/) (n = 168). The Harvard IRB approved Mas-
sachusetts and Southwest USA carriage studies described elsewhere [12,18,28,29]. The contri-
butions of isolates by GPS sites were approved by the respective institution’s IRB. These data
as well as publicly available and previously published data were anonymized for our analysis.
Available data included the year and country of isolation, isolation source, and limited patient
demographic data. To assess the temporal shift in prevalence of the three CC180 clades, we
tested the significance of changes in the proportion of isolates by clade for each sampling year
by comparing yearly proportions to 1000 random deviates of a Dirichlet distribution [30]. If
the temporal change in proportion was found to be significant, then the directionality of the
change was assessed. Current and past PCV (PCV7, PCV10, and PCV13) use data for coun-
tries where the serotype 3 CC180 sample was collected were queried from International Vac-
cine Access Center (IVAC) VIEW-hub website (www.view-hub.org, accessed April 5, 2017).
Fisher’s exact test was used to test the association between countries that introduced PCV and
serotype 3 clade emergence based on phylogenetic demography (See phylogenetic analysis
methods). Further, among countries that introduced PCV13, the correlation between the date
of introduction and changes in serotype 3 demography was assessed using Pearson’s correla-
tion coefficient. All statistical analysis and figure generation was performed using Rstudio
v1.0.143 with R v3.3.1.
Genomic analysis
For GPS isolates, raw sequencing data and de novo assemblies were downloaded from http://
www.pneumogen.net/gps/. GPS de novo assemblies were generated using a Velvet pipeline as
previously described [31]. The remaining sequencing data were downloaded from the NCBI
SRA database (See S1 File for a list of accession numbers). If only draft assemblies were avail-
able, paired-end 150 bp reads were generated using the BBMap’s RandomReads script. De
Population genomics of serotype 3 CC180 pneumococci
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007438 November 26, 2018 4 / 26
novo assemblies for non-GPS isolates were generated using SPAdes v3.10 as previously
described [18,32]. Assemblies were then annotated using Prokka v1.12 [33] and pangenome
analysis was conducted using Roary [34]. Assemblies constructed using simulated reads were
checked for variation in assembly metrics, annotation, and SNP diversity, in order to detect
any evidence of sequencing and assembly errors. Variants for 13 polymorphic pneumococcal
protein antigens—including pneumococcal surface proteins C and A (pspC and pspA)—were
determined by mapping raw reads to an antigen variant database using SRST2 as previously
described [27]. Quality filtered and trimmed reads were mapped to S. pneumoniae OXC141
(NCBI Reference Sequence: NC_017592), a Clade I, serotype 3 ST180/CC180 carriage isolate,
using SMALT v0.7.6. SNPs were called using SAMtools v1.3.1 [35], and were filtered requiring
QUAL>50, depth of coverage�5 and a minimum alternate allele frequency�0.75 [12,36].
Gubbins v2.1 was used to assess recombination, and coding sequences (CDSs) impacted by
recombination blocks were annotated and plotted using Circos [37,38]. Last, we assessed non-
synonymous mutations and recombination in the comCDE operon, which has previously been
implicated in the low competence of CC180 compared to other pneumococcal lineages [18].
Phylogenetic analysis
A maximum likelihood (ML) phylogeny was inferred from a recombination-censored SNP
alignment using RAxML v8.2.1 with an ASC_GTRGAMMA nucleotide substitution model,
Lewis ascertainment bias correction, and 100 bootstrap replicates [39]. The ML phylogeny was
rooted using strain AP200 (accession # CP002121), a serotype 11A, ST62 S. pneumoniae inva-
sive isolate, which was found to be immediately basal to the CC180 clade [40]. After assigning
isolates to major clades, Gubbins was run independently on the sequence alignments from
each clade to identify putative recombination events. ML phylogenies from recombination-
censored alignments were used to test temporal signal by assessing correlation between strain
isolation date and root-to-tip distance. To reduce bias in coalescent analysis due to differences
in sampling over the study period, isolates were subsampled using a uniform probability from
each year and spatial location (country and region), as recommended in [41]. To verify tempo-
ral signal, we performed date randomization tests on the down-sampled datasets, whereby the
sampling times of sequences are shuffled and evolutionary rates are compared to correctly
assigned time estimates (see S1 Methods) [42,43]. For major Clade I (hereon referred to as
Clade I-α) and Clade II, coalescent analysis was performed using BEAST v1.8.4 (see S1 Meth-
ods) [44]. Parameter estimates for the evolutionary rate, root height, and Ne were obtained
from the best-fit model and compared between clades. Last, to infer the ancestral geographic
location and migration history of Clade II, we used the structured coalescent implemented in
Beast 2.4.4 specifying the region of collection as the geographic location for each tip [45,46].
Additionally, BEAST XML code has been made available (https://github.com/c2-d2/Projects).
Phenotypic and genotypic antibiotic resistance
Antimicrobial resistance (AMR)-associated genes and SNPs were identified with ARIBA using
ARG-ANNOT and CARD databases [47,48]. Penicillin MICs were predicted using WGS data
to type transpeptidase domains of penicillin binding proteins [49]. Genotypic antibiotic resis-
tance was validated among strains with available broth dilution data using published CLSI
breakpoints for penicillin, chloramphenicol, erythromycin, clindamycin, and tetracycline. For
isolates that possessed multiple AMR-associated genes, annotated de novo assemblies were
investigated to identify conjugative transposons. Transposons were identified through review
of de novo assembly annotations and their presence/absence among strains was confirmed by
mapping sequencing reads to transposons as described above.
Population genomics of serotype 3 CC180 pneumococci
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Assessment of capsular polysaccharide variations
First, we assessed variations in the CPS loci by abstracting the region from reference-based
genome assemblies and generating an ML phylogeny using RAxML with GTRGAMMA sub-
stitution model and 100 bootstrap replicates. The mean pairwise nucleotide difference was also
calculated enforcing pairwise deletion of missing sites. CPS loci were manually inspected for
recombination events using the output from Gubbins to determine the potential role in clade
variation.
To investigate phenotypic variations related to the serotype 3 CC180 capsular polysaccha-
ride between Clades I-α and II and potentially explain the recent emergence of Clade II, we
assessed surface charge (zeta potential), capsular release, and opsonophagocytic killing. Zeta
potentials among representative Clade I-α (n = 5) and Clade II (n = 3) serotype 3 strains from
Massachusetts were compared to S. pneumoniae serotype 3 ST378 laboratory strain WU2 and
ΔCPS WU2 as previously described [25]. Capsular release, a mechanism by which type 3 CPS
interferes with antibody-mediated killing and gains protection by anti-CPS antibodies, was
compared among Clade I-α (n = 3) and Clade II (n = 3) serotype 3 isolates from Massachusetts
to strain WU2 as previously described [50]. To assess the efficiency of antisera against serotype
3 CC180 to opsonize pneumococci for uptake and killing by differentiated polymorphonuclear
leukocytes, we used an opsonophagocytic killing assay (OPKA) [51]. The killing assays were
performed at multiple dilutions using PCV13 antisera and antisera generated from type 3 poly-
saccharide (PS) (see S1 Methods) [52]. All Clade I-α and II strains studied in phenotypic assays
are marked on the ML phylogeny.
Results
Population structure
The serotype 3 CC180 isolates (n = 301) included in this sample came from 24 countries from
North America (38.9%), Western Europe (17.9%), Asia (14.6%), Eastern Europe (14.3%),
Africa (7.6%), and South America (6.3%) collected from 1993–2014. The ML phylogeny,
inferred from a core genome alignment of 15,327 SNP sites, improved the resolution of the
three major lineages identified in previous work. Clade I and the previously described Clade II
together form a single monophyletic lineage, distinct from the previously described Clade III
(Fig 2A). Applying an out-group roots the phylogeny on the branch between those strains
previously described as Clades II and III, indicating that the previous clade naming scheme
was inaccurate. To reflect this, and the fact that we now find two rather than three monophy-
letic lineages, we refer to Clades I-α and I-β (formerly Clades I and II) and Clade II (formerly
Clade III). Clade I-α isolates made up the majority of the sample (68.4%), but a significant pro-
portion is made up of Clade I-β (12.3%) and Clade II (19.3%). The expanded sample now
shows a single deep branching lineage containing Clade I-β, which is polyphyletic and sub-
tends Clade I-α. Clade II is further subdivided into three well-supported subclades that are dis-
tinct in terms of genome content (see below). Following removal of regions that were inferred
to have been introduced by recombination, the nucleotide diversity of Clade II was signifi-
cantly greater than that of Clade I-α [mean pairwise SNP distance 98.0 (SE 2.1) vs. 112.7
(SE 3.6)].
Phylogeography and country-level vaccine use history
The proportion of isolates belonging to Clade II has significantly increased over time from
1999–2001 (11%) to 2011–2014 (41%) (4.2, 95% CI: 1.9–9.0, p<0.0001) with the largest
increase occurring in North America (Fig 2B). During the same time Clade I-α has
Population genomics of serotype 3 CC180 pneumococci
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Fig 2. A) Rooted maximum likelihood phylogeny of S. pneumoniae serotype 3 CC180 isolates (n = 301) inferred from an alignment of 15,327 SNPs present in the core
genome. Phylogeny was out-group rooted using strain AP200 (accession # CP002121) a serotype 11A, ST62 S. pneumoniae invasive isolate, which was found to be
immediately basal to the CC180 clade in a global phylogeny of pneumococcal reference genomes and therefore represented the closest out-group. Bootstrap values
from 100 replicates are labelled on major clades and epidemiologically relevant sub-clades. Additional values can be found in the supplemental phylogeny. Mean
pairwise within- and between-clade SNP difference are presented in the grey shaded box with colors corresponding to the phylogeny. B.) World map illustrating
sampled countries and regions with respective proportion of isolates belonging to Clade I-α, I-β, and II. Countries are colored according to region and pie charts
represent the proportion of isolates belonging to major serotype 3 clades. The size of the pie chart is scaled to the proportion of strains sampled from each region.
Mapping was performed using R package maps v3.3.0. C) Proportion of clade membership by three-year collection window. The proportion of clade membership by
region over-time is displayed on the top of the figure. Pie charts are scaled by the number of isolates sampled from a geographic region by time window (i.e., column).
The overall proportion of clades for each time window is presented on the bottom of the figure.
https://doi.org/10.1371/journal.ppat.1007438.g002
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significantly decreased, and Clade I-β remained largely unchanged. In the present sample,
Clade II was first reported in Asia in 1999, but is now globally distributed, making up a large
proportion of samples from Asia, Africa, and North and South America (Fig 2B). However,
Clade II was only observed twice among 97 European strains (Table 1), first appearing in 2003.
Clade I-α was the most prevalent in the sample and found to be globally distributed, while
Clade I-β isolates appear more common in samples from South America and Asia (Fig 2B).
Clades I-α and II had significant temporal signal, identified by root-to-tip date correlation
(S1 and S2 Figs). A date randomization test also showed significant temporal signal for Clade
II, but date randomizations for Clade I-α failed to reach ESS values >200 despite chain length
(S3 Fig). Model comparison using Bayes factors calculated from MLEs identified both Clades
I-α and II fit a GMRF SkyGrid demographic model and relaxed molecular clock (S1 Table).
In addition, the exponential demographic model was preferred to the constant for Clade II
but rejected Clade I-α. Evolutionary rates were not significantly different between the two
clades; however, the 95% Highest Posterior Density (HPD) for Clade II was wider (S4 Fig),
owing to a greater coefficient of variation (S = 0.38 vs 0.21 for Clades II and I-α, respectively)
and indicating higher rate variation among branches. Clade II was significantly younger, with
an estimated most recent common ancestor (TMRCA) of 1968 [95% HPD: 1939–1989] (S1
Table). The effective population size (Ne) for Clades I-α and II have been increasing, as
demonstrated by the SkyGrid Ne plots (Fig 3) and rejection of the constant population size
demographic model (S1 Table). Further, the exponential model for Clade II suggested the pop-
ulation was exponentially increasing (mean exponential growth rate = 0.054 [95% HPD:
5.11x10-3, 0.11]).
Phylogeographic migration models of Clade II using the structured coalescent achieved suf-
ficient mixing (i.e., ESS values>200) for all parameters; however, posterior probabilities for
migration rates between geographic regions were not significant (<0.30). Therefore, we were
unable to infer the ancestral geographic locations of Clade II isolates. We noted, however, that
in both ML and Bayesian time-scaled phylogenies, the Asian clade made up of isolates from
Hong Kong is proximally basal to the major North American clade (Figs 4 and 5). Further, iso-
lates from Hong Kong possess a unique Tn916-like transposon shared only with isolates found
in the dominant North American clade (Fig 5) (see below).
Clade II was found in 11 of 24 countries, 10 of which introduced PCV during our study
period (Fig 6). There was no association between countries that introduced PCV13 and the
observation of an isolate belonging to Clade II (Fisher’s Exact, 4.2 95% CI: 0.3–239.9, p = 0.3).
There was also no correlation between year of vaccine implementation and the year of first
identification of an isolate belonging to Clade II (Pearson’s correlation = 0.17, 95% CI: -0.52–
0.72, p = 0.64). In general, there was no clear pattern among countries in vaccine introduction
and Clade II presence. However, in the USA, where annual data was most complete, yet sparse,
there was a significant change in the proportion of Clade II and Clade I-α isolates when com-
paring the four years prior to the introduction of PCV13 to the four years after (2005–2009 vs.
2010–2014, Fisher’s Exact, 3.6 95% CI: 1.3–10.7, p = 0.01).
Table 1. Clade composition of CC180 serotype 3 isolates by geographic location. Percentages are based on 295 isolates with available collection date and country.
Clade Eastern Europe
(n = 43)
Western Europe
(n = 54)
North America
(n = 117)
South America
(n = 15)
Africa
(n = 23)
Asia
(n = 43)
Total
Clade I-α (n = 204) 90.7% 98.1% 74.4% 6.7% 69.6% 18.6% 69.2%
Clade I-β (n = 35) 7.0% - - 73.3% 4.3% 46.5% 11.9%
Clade II (n = 56) 2.3% 1.9% 25.6% 20.0% 26.1% 34.9% 19.0%
https://doi.org/10.1371/journal.ppat.1007438.t001
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Recombination and genomic variation
We sought to identify whether the clades we identified above showed differences in the
historical contribution of recombination, which has been previously considered important in
adaptation to clinical interventions [53]. We found that Clades I-α, I-β, and II experienced
substantial recombination, impacting 1,179 CDS and diversifying gene content among clades
(S5 and S6 Figs). The ratio of polymorphisms introduced through recombination compared to
those introduced by mutation (r/m) for the entire sample was estimated at 1.76 with a mean
recombination tract length of 12.3 kb. When independently assessed, we found Clade I-α pos-
sessed the lowest r/m among the three tested clades as well as the smallest tract length for
recombination events (Table 2). Forty-two unique recombination events affecting 582 CDS
occurred on the branch segregating Clade II and I-β resulting in an r/m of 4.0 (S5 Fig). Com-
parison of r/m values between internal and terminal branches of the phylogeny suggests that
the great majority of recombination events in CC180 are located on internal branches,
although more recent events have occurred especially in Clade I-β (Table 2). We subsequently
examined the comCDE operon, encoding the competence stimulating peptide and two-com-
ponent regulatory system, and the associated regulatory genes comAB to identify any varia-
tions among these loci between the clades. Overall, the comCDE operon was markedly
Fig 3. Effective population size (Ne) comparison of serotype 3 CC180 Clades I-α and II. Ne values were estimated
using BEAST 1.8.4, enforcing a GMRF SkyGrid demographic model and relaxed molecular clock. The Ne of Clades I-α
and II have been increasing with Clade II in particular, increasing exponentially base on phylodynamic model
comparison.
https://doi.org/10.1371/journal.ppat.1007438.g003
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uniform (mean pairwise SNP distance = 1 SE 0.5); however, we found a non-synonymous
mutation in comD (AA104: Pro->Ser) among Clade I-β and II strains, which segregated them
from Clade I-α. Further, while competence factor transporting protein comA was identical
among the three clades, competence factor transport accessory protein comB was more
diverged between Clades I-β/II and Clade I-α (mean pairwise SNP distance = 1.7 SE 0.7), as a
result of a recombination event that affected all strains belonging to Clade II.
Recombination impacted a substantial proportion of the genome, focused in known recom-
bination “hotspots” (Fig 7). As a result, we observed significant variation in mobile genetic ele-
ments (MGE) and gene content, including polymorphic protein antigens, evident through
comparison of de novo assemblies and patterns of recombination. Pangenome comparison
identified 1,437 core genes, as well as variations in gene content among clades (S7 Fig). Two
notable differences in MGE that resulted in gene content variation among CC180 clades were
the presence of a Tn916-like conjugative transposon in Clade II strains (discussed below) and
Fig 4. Maximum clade credibility, time-scaled phylogeny of CC180 serotype 3 (PMEN31) Clade II isolates estimated using the structured coalescent model
implemented in BEAST2. Branches are colored by geographic region and thickness is scaled values of posterior probabilities for geographic migration. Posterior
probabilities for internal branches were all<0.30, precluding assessment of ancestral geographic dispersion.
https://doi.org/10.1371/journal.ppat.1007438.g004
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Fig 5. Phylogeny, polymorphic protein antigen variants, and antibiotic resistance. Midpoint rooted maximum-likelihood phylogeny corresponding to Fig 2A with
geographic region of isolation represented as colored tip shapes. Clades I-α, I-β, and II are shaded consistent with Fig 2A. Bootstrap values from 100 replicates are
provided for major clades and sub-clades (see supplemental phylogeny for all values). Strains used in opsonophagocytic killing assay (asterisk) and surface charge
experiments (double dagger) are indicated on the phylogeny. Corresponding protein antigen variants for SP1294, NanA, StrH, PspC, and PspA are illustrated on the
left half of the heatmap. Eight other protein antigens are excluded due to a lack of variation in the sample. The presence and absence of AMR-associated genes are
illustrated on the right half of the heatmap. The last column of the heatmap indicates genotypic antibiotic resistance that was confirmed by phenotypic testing (broth
dilution or disk diffusion).
https://doi.org/10.1371/journal.ppat.1007438.g005
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the absence of the 33.3 kb prophage ϕOXC141 in Clades I-β and II [54,55]. The ϕOXC141 pro-
phage, which was putatively acquired by an ancestor of Clade I-α, has been lost multiple times
by members of Clade I-α (Fig 5). Notably, it is absent from some Clade I-α isolates from North
America, which includes a number of strains from Massachusetts that form a distinct subclade.
In all, ϕOXC141 is present in 71% of Clade I-α isolates and 50% of CC180 serotype 3 strains
overall.
Among 13 tested polymorphic protein antigens, five were found to be variable, including
membrane associated protein SP2194, cell-wall anchored proteins neuraminidase A (NanA)
and β-N-acetylhexosaminidase (StrH), and surface exposed proteins pspC and pspA (Fig 5).
SP2194 encodes the ATP-binding subunit of Clp protease and is involved in the expression of
the comCDE operon, which plays an important role in competence, survival, and virulence of
pneumococci [56]. Three internal and three terminal branches contain recombination events
that have impacted SP2194. Major events occurred on each internal branch leading to Clades
Fig 6. PCV implementation by country and year based on IVAC data from 1999–2014. For each country, the
year is shaded based on PCV-7, PCV-10, and PCV-13 vaccine usage. Boxes marked with a dot designate the year in
which a Clade II isolate was first observed. �Malaysia and China have yet to introduce PCV as part of their national
immunization program. Pneumococcal vaccine use in China varies regionally. Data from China reflects PCV use in
Hong Kong where serotype 3 isolates were sampled. ��PCV has been available in Thailand as an optional vaccine
through the National Vaccine Program since 2006. However, uptake is<5% in children under 5. ���In Poland, PCV
was available to parents through private pay. Population based vaccination, without catch-up campaign, was
introduced in 2017 using PCV10.
https://doi.org/10.1371/journal.ppat.1007438.g006
Table 2. Recombination among CC180 lineages. The number of polymorphisms introduced via recombination to mutation (r/m) and the number of recombination
events to polymorphisms introduced by mutation (ρ/Θ) are reported for internal and terminal branches of dominant clades. Recombination occurring on internal
branches is considered ancestral while terminal branches represent recent events. The overall recombination rates are also reported.
Clade/s Mean tract length (bp) r/m ρ/Θ
Internal Terminal Overall Internal Terminal Overall
Clade I-α 2,590.8 0.11 0.07 0.09 0.00 0.01 0.01
Clade I-β 11,457.6 4.15 2.33 3.35 0.03 0.02 0.03
Clades I-β+II 10,629.1 6.18 1.43 4.00 0.05 0.02 0.04
Clade II 9,446.5 5.34 0.32 2.67 0.05 0.01 0.03
CC180 10,219.9 3.26 0.54 1.76 0.03 0.01 0.02
https://doi.org/10.1371/journal.ppat.1007438.t002
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I-α, I-β, and II, and as a result, SP2194 is significantly diverged among the three clades (mean
between clade SNP difference = 31.1 SE 3.8; p-distance 0.013 SE 0.002). Protein antigen genes
pspA and pspC are known recombination “hotspots” [57], and here we find that recombination
generated variation that subsequently become fixed in dominant clades and sub-clades. The
Family 2 pspA variant was largely associated with Clades I-α and I-β, while the Family I variant
Fig 7. Circos plot of recent and ancestral recombination events inferred among CC180 serotype 3 isolates. Moving from the inner ring outward, rings show a
histogram of unique recombination events occurring among isolates belonging to Clades I-β, I-α, and II, respectively, followed by a heatmap of cumulative recombination
events. Finally, the outermost ring displays annotations of notable genes and genomic regions corresponding to the location on the OXC141 reference genome.
https://doi.org/10.1371/journal.ppat.1007438.g007
Population genomics of serotype 3 CC180 pneumococci
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007438 November 26, 2018 13 / 26
was associated with Clade II [58]. Using the pspC groupings—based on structural and nucleo-
tide variation proposed by Iannelli et al.—we found that Clades I and II had non-overlapping
sets of pspC variation: indeed, Clade I possessed a pspC variant consistent with Groups 7/8/9,
whereas Clade II variants included Groups 1/5 and 2/3/6 [59]. Hence, we have good evidence
that the clades present divergent protein antigenic profiles to the human immune system.
Antimicrobial-resistance (AMR) associated genes
We found variation among clades in genes associated with AMR. Clade II isolates from Hong
Kong (n = 6) and USA (n = 9) harbored a 37.6 kb Tn916-like conjugative transposon possess-
ing tetM and ermB (S8 Fig). These strains also possess chloramphenicol acetyltransferase (cat).
For 13 of 15 strains with Tn916, antibiotic susceptibility testing was available in GPS metadata
or from previous publications [21]. In general, Tn916 positive isolates exhibited high-level
resistance to tetracycline, clindamycin, and erythromycin. However, three USA strains were
susceptible to macrolides as the result of a previously described ermBS marker, a missense sub-
stitution within ermB that is associated with erythromycin and clindamycin-susceptibility
[60]. Additional phylogenetic analysis of 26 core transposon clusters of orthologous genes
(COGs) as well as genealogies of Int-Tn, ermB, and tetM illustrated that there were in fact two
acquisitions of genetically similar Tn916 transposons among Clade II isolates (S8 Fig). In both
of these instances, the transposon was first observed in a Clade II isolate collected from Hong
Kong, which lie basal to a clade of USA isolates possessing the respective variant.
Other notable differences between clades include the presence of tet32 in eight Clade II iso-
lates, which is distinct from tetM carried on Tn916 transposons. In addition, the multi-drug
efflux-pump pmrA was present in almost all Clade I-β and II isolates. We were able to confi-
dently type PBP transpeptidase domains of 270 isolates to predict penicillin resistance. All
were predicted to be penicillin-susceptible; however, four Clade II isolates possessed a PBP
profile with first-step β-lactam resistance (transpeptidase domain profile 2-0-111, predicted
MIC of 0.06) and were later confirmed by broth dilution to have penicillin MICs ranging from
0.05 (n = 1) to 0.06 (n = 3). These four isolates also possessed Tn916. PBP profiles further dif-
ferentiated CC180 clades, with the majority of Clade I-α isolates possessing profile 2-3-2, and
Clades I-β and II strains profile 2-0-2 (S2 Table).
Capsular polysaccharide variation in phenotype
Interrogation of inferred recombination events showed that the CPS loci were unaffected by
homologous recombination (Fig 7). Furthermore, while the ML phylogeny estimated from the
alignment of CPS loci was clearly segregated between the dominant clades, the average pair-
wise nucleotide difference was only 1.6 (SE 0.4) SNPs (S9 Fig). However the absence of major
genotypic variation does not rule out relevant phenotypic variation, so we assessed phenotype
of representative Clade I-α (n = 5) and Clade II (n = 3) serotype 3 strains for three properties
previously associated with success: zeta potential, capsule shedding and resistance to neutro-
phil-mediated opsonophagocytosis. The zeta potential measures surface charge, which varies
among capsular type and has previously been associated with differences in prevalence and
duration of carriage, with more negatively charged capsules being carried for longer [25], but
while the surface charge of clade II isolates was slightly more negative among tested strains this
difference was not significant (S10A Fig). In addition, comparison of isolates from Clades I-α
and II found no significant difference in capsule shedding (S10B Fig). We did observe differ-
ences in neutrophil-mediated opsonophagocytic killing. Clade II isolates were killed in the
presence of antisera against both PCV13 and type 3 polysaccharide. In contrast, Clade I-α iso-
lates were not susceptible to killing in the presence of type 3 polysaccharide antisera, and only
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one out of the three tested Clade I-α isolate was killed in the presence of high titer PCV13
antisera.
Discussion
Serotype 3 pneumococci belonging to CC180, the most dominant serotype 3 clone globally,
remain epidemiologically important. Over the last decade, Clade I-α and Clade II have
increased in effective population size, with Clade II becoming particularly prevalent in Asia
and North America and emerging in other regions where it has historically not been observed.
Phylogenetic analysis demonstrates that Clade II is significantly diverged in both core genome
nucleotide diversity and genome content, with multiple recombination events having occurred
at the base of the lineage. Temporospatial surveillance data, coalescent analysis, and molecular
epidemiology evidence suggests that the diaspora of Clade II may have originated in Southeast
Asia in the 1990s and subsequently spread worldwide over two decades, concomitantly grow-
ing in prevalence. In North America, Clade II now makes up more than half of the post-
PCV13 serotype 3 CC180 population. While neither use of PCV at a country level, nor timing
on PCV introduction appears to be clearly associated with the rise of Clade II, we find that
Clade II has divergent surface protein antigens and increased prevalence of antibiotic resis-
tance compared to the other CC180 clades. These two observations are likely contributors to
the recent increase in prevalence of Clade II.
While phylogeographic analysis was unable to infer confidently the ancestral migration
events that disseminated Clade II, the presence of Tn916 among strains from Hong Kong and
the USA provides molecular evidence of migration from Asia to North America. In at least
two instances, distinct Tn916 transposons are found among isolates from Hong Kong, which
are basal to strains from North America. This suggests the acquisition of this transposon pre-
dates the emergence of Clade II in North America; thus, strains circulating in Asia were the
ancestral populations of a large proportion (~50%) of North American Clade II isolates. Fur-
ther, multiple introductions of serotype 3 Clade II isolates to the USA from Asia may have
occurred. Tn916 confers macrolide resistance, with the rare exception of strains possessing a
mutation in ermB [61]. Macrolide resistance has previously been described among serotype 3
ST180 isolates from Italy and Japan in 2001 and 2003, respectively, where macrolide-resistant
serotype 3 strains are prevalent [19,62,63]. In addition, macrolide and tetracycline resistance
ST180 strains have been reported from Taiwan (1997), Spain (2002), and more recently, Can-
ada (2011–14), and Germany (2012) (https://pubmlst.org/). Unfortunately, MLST is not dis-
criminating enough to distinguish between the CC180 lineages we discuss here, and as
genomic data are not available for these isolates, we cannot determine how they relate to our
sample. However, as macrolide resistance among CC180 serotype 3 isolates is relatively rare
and largely isolated to Clade II, the early identification of macrolide resistance strains from
Hong Kong, Taiwan, and Japan may represent the ancestral population of Clade II putatively
possessing Tn916, further supporting a Southeast Asian origin and implicating antibiotic resis-
tance as a possible contributor to the recent success of Clade II.
As PCV use has previously been associated with major changes in pneumococcal popula-
tion structure including replacement of vaccine serotypes by non-vaccine serotypes (i.e., post-
vaccine serotype replacement) [64,65], we considered that serotype 3 may have increased in
those settings where PCV was introduced. Moreover, variation in effectiveness of the serotype
3 component of PCV13 among CC180 clades may have disproportionally precipitated an
increase in Clade II. Here, we find little evidence that PCV use, albeit at a country level, has
shaped the serotype 3 CC180 population. However, there are limitations in these comparisons,
as they ignore important factors such as phylogenetic population structure (i.e., whether Clade
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II was already present), age of cases, and details of vaccine roll-out (e.g., timing, targeted age
groups, and vaccine coverage). Unfortunately, these data are incomplete for a number of
cases/countries, precluding an in-depth analysis of the putative association of PCV with emer-
gence of Clade II. Nonetheless, since serotype 3 is a non-vaccine serotype in regions where
PCV-7, PCV-10, and, arguably, PCV-13 has been introduced, removal of vaccine serotypes
may have precipitated the increase in serotype 3. Further, as we posit below, phenotypic and
genomic variation between Clades I-α and II may have led to a competitive advantage to Clade
II, which did not exist prior to vaccine introduction.
Historically, antibiotic resistance among serotype 3 CC180 strains has been low. This is
because the previous population was dominated by isolates from Clade I, which is largely
devoid of AMR-associated genes and mutations. This may result from the high invasiveness of
serotype 3 and its relatively short carriage duration, which in turn reduces bystander antibiotic
exposure through treatment of other infections [66]. Here we find chloramphenicol, macro-
lide, tetracycline, and first step penicillin resistance more frequent among Clade II isolates
when compared to Clade I isolates. It is not clear whether these are directly linked to the recent
increase in prevalence and emergence in previously unobserved regions. However, increased
macrolide usage in North America has previously been associated with increases in macrolide
resistant Staphylococcus aureus and nonsusceptible S. pneumoniae [67,68].
In addition to variations in AMR-associated genes, we also find that MGE and polymorphic
protein antigens varied among Clades I-α, I-β, and II. The previously described ϕOXC141 was
generally absent among Clades I-β and II and has been lost by a North American sub-clade of
Clade I-α [54,55]. Temperate bacteriophages may be associated with fitness defects among
pneumococci or changes in virulence and competence [69,70]. Whether the presence or
absence of ϕOXC141 relates to the relative success of serotype 3 CC180 clades is unclear. How-
ever, the absence of ϕOXC141 from Clade II as well as the loss of the phage by a subclade of
North American Clade I-α strains remains notable and warrants further investigation. Con-
tributing to genomic variations among clades, pspA, pspC, and SP2194 (ATP-dependent Clp
protease) were found to vary. Natural immunity to protein antigens is generated through naso-
pharyngeal colonization, and this immunity may protect against colonization and invasive dis-
ease [27,71]. Protein antigen variants were generally conserved among Clade I-α isolates and
varied in Clades I-β and II. As protein antigen variants are serologically distinct, variations in
antigen profiles among CC180 clades could impact relative transmissibility and virulence,
resulting in differences in carriage duration, transmission, and invasive capacity [27,59,72,73].
For example, in previous comparisons of Family 1 and 2 pspA variants in isogenic strains of
serotype 3 (WU2), Family 2 mutants were slightly less virulent and bound less human lactofer-
rin, impacting nasopharyngeal colonization [74]. Here, we find that Clade II isolates largely
possess the Family 1 pspA variant. Further, variants of pspC differentially bind factor H and
generate distinct antibody responses, promoting immune escape [75]. Most isolates in Clade
I-α possess a pspC variant corresponding to Groups 7/8/9, which have been grouped here
because they share the same structural organization [59]. In contrast, Clades I-β and II possess
multiple polymorphic pspC variants interspersed throughout the topology of the clades, sug-
gesting that multiple recent recombination events have generated variation in this known
recombination hotspot as well as a diversified antigenic profile. Taken together, differences in
antigenic profiles add to the immunological variability among CC180 clades. Under a model
of immune selection, where novel and beneficial combinations of protein antigens are posi-
tively selected, this could have led to an increase in the frequency of Clade II isolates. While
the epidemiological implications of these finding require further investigation, together with
antibiotic resistance, antigenic variation presents another possible contributor to the success of
Clade II.
Population genomics of serotype 3 CC180 pneumococci
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007438 November 26, 2018 16 / 26
The population of serotype 3 has been previously thought to be largely clonal, clustering
into a group of closely related PFGE patterns corresponding to the Netherlands3–31 clone
[76]. Further, evolution of CC180 was thought to be driven primarily through nucleotide sub-
stitution and estimates of recombination rates based largely on Clade I-α suggested a compara-
tively lower rate to other PMEN clones [18], mainly dominated by micro-recombination
events [77]. However, the expanded global sample of PMEN31 serotype 3 genomes demon-
strates in detail how the prevalent lineages have diverged following significant ancestral recom-
bination events. While comparatively rare, recombination continues to shape the CC180
population, as terminal branches in all three clades show evidence of recent recombination
events. This inferred clonality likely resulted from the limited sample of type 3 isolates from
restricted geographies. Further, while serotype 3 is generally understood to show lower compe-
tence than other serotypes based on in vitro studies [18,78], we found that the emergent Clades
II and I-β have more evidence of historical recombination events (ρ/Θ) and a greater propor-
tion of macro-recombination events than the previously dominant Clade I-α. The Clade I-α
comCDE operon generates an antisense transcript, an observation that could be relevant to the
low historical recombination rate of Clade I-α [18]. Amino acid changes in the comCDE, spe-
cifically comD, also segregate Clade I-α from I-β, and II. We also found variations in the Clp
protease gene, which regulates the comCDE operon, and is therefore associated with compe-
tence rates among pneumococci and other bacteria [56,79]. Increased recombination rates in
Clade II have the potential to generate a more diverse antigenic profile, which would be benefi-
cial under diversifying selection from the immune system. More recombination also facilitates
the acquisition of multi-drug resistance [80,81]; indeed, higher rates of recombination have
previously been associated with antimicrobial resistance [82]. Negative frequency-dependent
selection (NFDS) has been proposed as a mechanism for maintaining intermediate frequency
loci among pneumococci [83], and together with host immunity, may also explain serotype
coexistence [84] and vaccine-induced metabolic shifts [85]. One possible explanation for the
relative success of Clade II, is that it possessed a favorable repertoire of accessory loci, protein
antigen variants, or metabolic loci, which were selected for in the post-vaccine landscape. The
exact loci which are acted upon by NFDS are yet unknown; however, it could involve immune
selection of protein antigens, antibiotic resistance conferring gene, and bacteriophage preda-
tion defence [12,83]. Here, we find variation in all three between Clade I and II.
Because serotype 3 pneumococcal strains possess a mucoid capsule and release significantly
more capsular polysaccharide during in vitro growth and infection in mice, it is hypothesized
that this soluble polysaccharide absorbs anti-capsular antibody, effectively impeding antibody-
mediated killing in vitro and in vivo [24,26,52]. We found that Clades I-α and II both shed
CPS during growth; however, the amount of CPS released did not significantly differ between
the two clades. Another phenotype that has been found to correlate with increased survival
due to resistance from phagocytosis by human neutrophils, and contribute to success in naso-
pharyngeal carriage is low surface charge, measured as zeta potential [25]. We therefore com-
pared this between Clades I-α and II and found no significant difference in charge between
clades, suggesting their capsular properties are similar. Where we did find significant pheno-
typic differences between the clades, it was not easy to relate these differences to the apparent
increase in Clade II following PCV13 introduction; we initially hypothesized that antisera
against PCV13 and type 3 polysaccharide might be more effective against isolates from Clade
I-α, explaining its apparent decline. However, for both Clades I-α and II, neutrophil-mediated
opsonophagocytic killing occurred only at high antibody levels. Clade I-α isolates appeared to
be resistant to killing by PCV13 antisera, while Clade II isolates were more readily killed. The
resistance of Clade I isolates to opsonophagocytic killing is consistent with the low efficacy of
PCV13 on serotype 3 invasive disease incidence [10,86], but difficult to link to the recent
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emergence of Clade II. However, these results should not be considered a direct representation
of vaccine effectiveness, because opsonophagocytic killing may be a poor proxy for the ability
to colonize and transmit. Moreover, opsonophagocytic killing only occurred at high titers.
Our findings are consistent with those of other groups, suggesting that higher antibody con-
centrations are needed for killing in vitro [52]. They also demonstrate that closely related bac-
teria with the same capsule do not necessarily behave similarly in the face of vaccination.
Together, our findings further support the involvement of anti-protein antibodies in medi-
ating anti-serotype 3 immunity. Anti-protein antibodies may act in synergy in vivo with antic-
apsular antibodies to mediate pneumococcal killing. This is an intriguing hypothesis in light of
our other findings about the differences in protein variant composition among serotype 3
strains. These differences in protein composition underscore the need for better evaluation of
the role that anti-protein antibodies have in mediating anti-pneumococcal protection. Overall,
the role of these in recent dynamics of serotype 3 epidemiology requires further study.
Serotype 3 remains an epidemiologically important serotype, continuing to cause invasive
disease and increasing in carriage prevalence in North America. Here, we explore multiple epi-
demiological, genotypic, and phenotypic factors associated with the persistence of serotype 3 in
carriage and disease. We found that the recent success of CC180 is related to an increasing
clade, which is distinct from the previous population’s antigenic composition, antibiotic suscep-
tibility, and competence. Based on OPKA, we also found evidence to support the low-observed
efficacy of PCV13 against serotype 3, which was previously dominated by CC180 Clade I-α in
Europe and North America. Optimistically, the efficacy of PCV13 against the emergent Clade II
may be higher; however, more in vitro and in vivo studies are required to confirm this finding.
Our study is not without limitations. While we base our analysis on the largest collection of
extant CC180 genomes, geographic and temporal sampling variations exist. To mitigate coa-
lescent analysis bias, we down-sampled according to published approaches. Additionally,
while the clonality and low diversity of Clade I-α may, at first approximation, suggest a more
recent origin, HPDs for the TMRCA of Clade I-α and II estimated through coalescent analysis
are non-overlapping and correspond to previously published estimates [18]. Further, despite
modest sampling from multiple geographies prior to 1999 (n = 34), Clade II isolates were not
observed. Our results instead indicate that the higher recombination rate and recent popula-
tion expansion of Clade II has led to its greater diversity. Lastly, our genomic results may be
affected by the accuracy of bioinformatic programs. Wherever possible, results were verified
using multiple approaches or manual inspection of the data.
Overall, our analysis emphasizes the need for routine, representative sampling of isolates
from disperse geographic regions, including historically under-sampled areas. We also high-
light the value of genomics in resolving antigenic and epidemiological variations within a
serotype, which may have implications for future vaccine development. As PCV usage and
antibiotic consumption expands globally, it is imperative to continue genomic and epidemio-
logical surveillance of pneumococci to detect the emergence of new lineages and monitor
changes in clinical presentation and severity, as these data have direct implications for preven-
tion and management of pneumococcal disease.
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S1 Fig. Root-to-tip correlation of Clade I-α. The tip dates, assigned using the collection date
of the isolate, is regressed upon the distance from the estimated root in the maximum likeli-
hood phylogeny to determine temporal signal.
(TIF)
S2 Fig. Root-to-tip correlation of Clade II. The tip dates, assigned using the collection date of
the isolate, is regressed upon the distance from the estimated root in the maximum likelihood
phylogeny to determine temporal signal. The corresponding taxa for the points in the upper-
right of the regression plot (indicated with a purple oval) are identified on the phylogeny to the
left. The root-to-tip correlation was also independently assessed for the sub-clade indicated in
purple and found to have a significant correlation.
(TIF)
S3 Fig. Date randomization test of Clade II. The estimated evolutionary rate for the BEAST
run with correct date assignment (T:true) appears at the far left of the x-axis, with the realiza-
tions for 10 date permutation runs to the right. Evolutionary rates in this figure are not cor-
rected for alignment length.
(TIF)
S4 Fig. Comparison of estimated evolutionary rate (top) and the most recent common
ancestor (TMRCA) (bottom) between Clades I-α and II. Evolutionary rate is scaled in SNPs/
site/year and TMRCA as the year of the estimated root height. Clade I is significantly “older”
then the recently emerged Clade II.
(TIF)
S5 Fig. A.) Distribution of inferred recombination block sizes for the entire sample and B.)
the major branch leading to Clade II (shaded and denoted with an asterisk). C.) Phylogeny
depicting the population structure of CC180 with Clade II shaded. In total, 236 Recombination
events impacted 1,179 coding sequences (CDS), with 42 of those events occurring on the
major branch leading to Clade II. The largest event, a 68,164 bp recombination block spanning
the region 407,458–475,621 on the OXC141 reference genome, impacting 70 CDS and 13
repeat regions. Pathways including these CDSs involve metabolism (n = 17), genetic informa-
tion processing (n = 10), signaling (n = 7), and environmental information processing (n = 5).
Notably, rpoE recombination and DNA repair protein (SPNOXC_04590) is included in this
region.
(TIF)
S6 Fig. Recombination analysis of clonal complex 180 isolates. The left side of the figure rep-
resents a maximum likelihood phylogeny of CC180 isolates inferred from a recombination-
censored alignment using Gubbins. The tree has been out-group rooted as described in the
methods and clades are ordered Clade I-α, I-β, and II, from top to bottom. On the top of the
figure is a linear depiction of the 2,036,867 bp S. pneumoniae OXC141 reference genome on
which recombination events are mapped. The bottom ribbon is a graph of recombination
events distributed linearly across the genome. The center panel indicated recombination
events among taxa. Red blocks display events occurring on ancestral branches and are there-
fore shared by a group of taxa. Darker shades of red indicate multiple events have occurred in
a genomic region. Blue blocks signify recombination events that occurred on terminal
branches and are unique to only one isolate. Output of Gubbins was visualized in Phandango,
which was used to construct this figure.
(TIF)
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S7 Fig. Venn diagram of core orthologous gene (COG) content of Clades I-α, I-β, and II.
COGs possessed by at least one individual within a clade were counted toward the “gene-pool”
for each comparison.
(TIF)
S8 Fig. Annotation of 37.6 kb Tn916-like transposon found in Clade II strains (top) and
phylogenies of 26 transposon core genes, Int-Tn, ermB, and tetM (bottom). The core
genome phylogeny and genealogies are labeled with length of alignment, mean pairwise dif-
ference (mpwd), and the ratio of non-synonymous to synonymous mutations (dN/dS). The
phylogenies show a clear delineation between two distinct transposons (blue and black tip
labels). In the ermB genealogy, two isolates that are macrolide susceptible are colored in
green.
(TIF)
S9 Fig. Maximum likelihood phylogeny inferred from 13.2 kb region comprising the cap-
sular polysaccharide (CPS) coding loci. Tips are labeled and colored by clade. Despite the
clear divergence of Clades I-α and II+I-β, very little nucleotide diversity exists.
(TIF)
S10 Fig. Comparison of surface charge (zeta potential measured in mV) (top) and capsule
shedding (bottom) between strains belonging to Clades I-α and II. ST3 Serotype 3 strain
WU2 is used as a control for both experiments and WU2ΔCPS is included in the analysis of
zeta potentials.
(TIF)
S11 Fig. Opsonophagocytic killing in the presence of antisera against type 3 polysaccharide
(A) and PCV13 (B) between isolates from Clades I-α and II. Antisera dilutions are labeled
on the x-axis and percent survival on the y-axis. Clade I-α isolates are on the left half of the x-
axis and Clade II appear on the right. Opsonophagocytic killing appears as a reduction in per-
cent survival with increasing concentrations of antisera.
(TIF)
S1 Table. Results of Bayesian phylogenetic analysis using Beast 1.8.4 for Clades I-α and II.
For each clade, strict (SC) and relaxed (RC) molecular clock models were compared for con-
stant, exponential, and GMRF Skygrid demographic models. Log marginal likelihood esti-
mates (MLE) from path-sampling (PS) and stepping-stone (SS) analysis were used to calculate
Bayes Factors for model comparison. Log Bayes Factors (BF) are specified for each molecular
clock and demographic model comparison. The date of the most recent common ancestor
(TMRCA) and evolutionary rate, scaled in SNPs/site/year are presented for the final model
with corresponding highest posterior densities (HPD).
(DOCX)
S2 Table. PBP transpeptidase domain variants (PBP1a-PBP2b-PBP2x) of 270 serotype
3 CC180 isolates. 2-0-111 possesses first step PBP-2X 111 allele that is associated with a
slightly elevated penicillin MIC of 0.06. All other profiles are associated with a penicillin MIC
(μg/ml)�0.03.
(DOCX)
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